Despite the many adaptations that have emerged over the course of 2020 and into 2021 to ensure oncology clinical trials are not disrupted, the number one challenge remains: adequate site selection.

Recent global events have created opportunities to reconfigure and transform how clinical trials operate. In doing so, it’s become very clear there is more than one way of doing things. There are a number of ‘next normal’ business considerations to be addressed as the industry moves forward into a post-COVID era.

Julie Martin, CEO & co-Owner of Scimega Research looks to the future and how to identify key operational process and adaptations to help US sponsors optimally navigate the ‘new normal’ in clinical trial operations in Canada and other geographic areas. In this webinar, Julie will share strategies for how to leverage lessons learned in 2020 and put these into action to maximize clinical development progress in 2021-22.

Strategies used to mitigate threats in 2020 & 2021
How to continue successfully navigating the transition period
Cutting-edge small & mid-size oncology biotech trials: where to run them & decision factors for our choice of regions in 2021-2022

Bonus Offer: Register now and receive immediate access to the white paper Expert Guidance to Key Advantages of Canadian Regulatory Landscape.

Keywords:

Speaker

Julie Martin, M.Sc., MBA, Lean certified, CEO & co-Owner, Scimega

Julie has been part of the team at Scimega, since 2013. Her passion for the business stems from knowing its expert oncology clinical development services add distinct value to industry stakeholders at a time when it’s needed most. As CEO, Julie’s vision is to secure the company’s long-term success by leveraging her in-depth industry expertise & business acumen. She equates that success with setting a clear vision for the organization’s continued sense of purpose. Julie is responsible for developing successful business strategies & leveraging industry opportunities all of which support the common vision she shares with her team. Her leadership & collaboration with the managing Board of Directors, with whom Julie has worked alongside since 2013, ensure the business excellence upon which Scimega has built its reputation. Julie plays a vital role in promoting Scimega’s expertise and showcasing Canada’s attributes as a formidable partner in global oncology drug development.

Message Presenter

Who Should Attend?

Clinical operations team leaders from small to mid-size biotech and biopharma companies managing complex oncology clinical studies will find the most benefit from this webinar. Relevant job titles include:

Manager/Associate/Assistant Director
Director/Head/Vice President Operations
CEO
CMO

What You Will Learn

In this webinar, participants will learn about:

Optimal strategies for navigating the ‘next normal’
Lessons learned to develop key operational process and adaptations
Complex oncology trials: where to run them now
What decision factors are expected to most influence your choice of region in 2021/22

Xtalks Partner

Scimega

Scimega is a niche Canadian CRO skilled in collaborative vendor teaming with a proven track record of 23 years unparalleled Canadian oncology experience. Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. Offering an optimal operations design robust enough to address an ever-changing clinical trial landscape, Scimega’s team of oncology experts go above-and-beyond for your study to provide:

✓ Identification and qualification of the right Canadian sites for your trial within just a few weeks thanks to our extensive network of Canadian Investigators.

✓ Site activation 50% faster than the industry average.

✓ In global oncology studies our Canadian sites frequently emerge among top enrollers. Like you, our clients develop cutting- edge oncology therapies, and they trust our results!